Literature DB >> 23053142

Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

A-C Müller1, J Lütjens, M Alber, F Eckert, M Bamberg, D Schilling, C Belka, U Ganswindt.   

Abstract

BACKGROUND AND
PURPOSE: This study reports on the treatment techniques, toxicity, and outcome of pelvic intensity-modulated radiotherapy (IMRT) for lymph node-positive prostate cancer (LNPPC, T1-4, c/pN1 cM0). PATIENTS AND METHODS: Pelvic IMRT to 45-50.4 Gy was applied in 39 cases either after previous surgery of involved lymph nodes (n = 18) or with a radiation boost to suspicious nodes (n = 21) with doses of 60-70 Gy, usually combined with androgen deprivation (n = 37). The prostate and seminal vesicles received 70-74 Gy. In cases of previous prostatectomy, prostatic fossa and remnants of seminal vesicles were given 66-70 Gy. Treatment-related acute and late toxicity was graded according to the RTOG criteria.
RESULTS: Acute radiation-related toxicity higher than  grade 2 occurred in 2 patients (with the need for urinary catheter/subileus related to adhesions after surgery). Late toxicity was mild (grade 1-2) after a median follow-up of 70 months. Over 50% of the patients reported no late morbidity (grade 0). PSA control and cancer-specific survival reached 67% and 97% at over  5 years.
CONCLUSION: Pelvic IMRT after the removal of affected nodes or with a radiation boost to clinically positive nodes led to an acceptable late toxicity (no grade 3/4 events), thus justifying further evaluation of this approach in a larger cohort.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053142     DOI: 10.1007/s00066-012-0169-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  44 in total

Review 1.  Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.

Authors:  Michel Bolla; Jean-Luc Descotes; Xavier Artignan; Philippe Fourneret
Journal:  BJU Int       Date:  2007-07       Impact factor: 5.588

2.  Healing of late endoscopic changes in the rectum between 12 and 65 months after external beam radiotherapy.

Authors:  Gregor Goldner; Richard Pötter; Alexander Kranz; Alexandra Bluhm; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2011-02-24       Impact factor: 3.621

3.  Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse.

Authors:  Anja M Weidner; Emile N J Th van Lin; Dietmar J Dinter; Tom Rozema; Stefan O Schoenberg; Frederik Wenz; Jelle O Barentsz; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2011-02-21       Impact factor: 3.621

4.  Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy.

Authors:  Lucia Perna; Filippo Alongi; Claudio Fiorino; Sara Broggi; Mauro Cattaneo Giovanni; Cesare Cozzarini; Nadia Di Muzio; Riccardo Calandrino
Journal:  Radiother Oncol       Date:  2010-03-20       Impact factor: 6.280

5.  Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Authors:  Jonathan B Ashman; Michael J Zelefsky; Margie S Hunt; Steven A Leibel; Zvi Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

6.  Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863.

Authors:  A Zurlo; L Collette; G van Tienhoven; L Blank; P Warde; J Dubois; W Jeanneret; G Storme; J Bernier; A Kuten; M Pierart; M Bolla
Journal:  Eur Urol       Date:  2002-08       Impact factor: 20.096

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Authors:  Nadeem Pervez; Cormac Small; Marc MacKenzie; Don Yee; Matthew Parliament; Sunita Ghosh; Alina Mihai; John Amanie; Albert Murtha; Colin Field; David Murray; Gino Fallone; Robert Pearcey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

9.  Radiotherapy in lymph node-positive prostate cancer patients - a potential cure? Single institutional experience regarding outcome and side effects.

Authors:  Gregor Goldner; Richard Pötter
Journal:  Front Radiat Ther Oncol       Date:  2008

10.  Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

Authors:  Hans T Chung; Ping Xia; Linda W Chan; Eileen Park-Somers; Mack Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-22       Impact factor: 7.038

View more
  5 in total

1.  Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration: interobserver agreement between radiation oncologists and therapists.

Authors:  B A Jereczek-Fossa; C Pobbiati; L Santoro; C Fodor; P Fanti; S Vigorito; G Baroni; D Zerini; O De Cobelli; R Orecchia
Journal:  Strahlenther Onkol       Date:  2013-08-17       Impact factor: 3.621

2.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

3.  Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy.

Authors:  F S Mounessi; P Lehrich; U Haverkamp; N Willich; T Bölling; H T Eich
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

4.  Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.

Authors:  Cordula A Jilg; Anja Leifert; Daniel Schnell; Simon Kirste; Natalia Volegova-Neher; Daniel Schlager; Gesche Wieser; Karl Henne; Wolfgang Schultze-Seemann; Anca-L Grosu; Hans Christian Rischke
Journal:  Radiat Oncol       Date:  2014-08-12       Impact factor: 3.481

5.  Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.

Authors:  Panayiotis Mavroidis; Kevin A Pearlstein; John Dooley; Jasmine Sun; Srinivas Saripalli; Shiva K Das; Andrew Z Wang; Ronald C Chen
Journal:  Radiat Oncol       Date:  2018-02-02       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.